10Nov 2024
Early Biologic Treatment in RA Linked to Difficult-to-Treat Cases

Early Biologic Treatment in RA Linked to Difficult-to-Treat Cases

The study investigated the progression of early rheumatoid arthritis (RA) in patients who escalated to biologic or targeted synthetic DMARDs (b/tsDMARDs) after failing to achieve control with methotrexate (MTX). Among 722 RA patients initially treated with MTX, 155 (21.5%) required b/tsDMARDs, with 29% meeting the EULAR criteria for difficult-to-treat (D2T) RA over a median follow-up of 72.6 months. Treatment retention rates for the first and second b/tsDMARDs were approximately 70% after one year, decreasing to 40% at five years. Predictors of D2T included a higher number of swollen joints, elevated pain scores, and autoantibody negativity. These results suggest that early escalation to b/tsDMARDs does not consistently prevent D2T in RA patients, particularly among those showing early refractoriness to MTX and lacking autoantibodies.

  • #orthopaedics

Like

Save

Share